Inverse agonism and neutral antagonism at wild-type and constitutively active mutant delta opioid receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 313, Issue 1, 2005, Pages 410-421

  Tryoen Toth P ^a   Decaillot F M ^b   Filliol, D ^a   Befort, K ^a   Lazarus, L H ^c   Schiller, P W ^d   Schmidhammer, H ^e   Kieffer, B L ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^e UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYL 4,5ALPHA EPOXY 14BETA ETHOXYINDOLO[2',3':6,7]MORPHINAN 3 OL; 17 ALLYL 4,5ALPHA EPOXY 14BETA METHOXY 1' METHYLINDOLO[2',3':6,7] MORPHINAN 3 OL; 17 CYCLOPROPYLMETHYL 4 METHOXYBENZOFURO[2',3':6,7]MORPHINAN 3,14BETA DIOL; 17 CYCLOPROPYLMETHYL 4,5ALPHA EPOXY 14BETA ETHOXYBENZOFURO[2',3':6,7]MORPHINAN 3 OL SALICYLATE; 17 CYCLOPROPYLMETHYL 4,5ALPHA EPOXY 14BETA ETHOXYINDOLOL[2',3':6,7]MORPHINAN 3 OL; 17 CYCLOPROPYLMETHYL 4,5ALPHA EPOXY 14BETA METHYLINDOLO[2',3':6,7]MORPHINAN 3 OL; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; 7 BENZYLIDENENALTREXONE; DELTA OPIATE RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HS 378; HS 414; HS 464; HS 510A; HS 531; HS 595; MESYLIC ACID DERIVATIVE; MORPHINAN DERIVATIVE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; NALTRIBEN; NALTRINDOLE; NALTRINDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG POTENCY; DRUG RECEPTOR BINDING; EMOTION; GENE MUTATION; HUMAN; HUMAN CELL; INVERSE AGONISM; NEUTRAL ANTAGONISM; NOCICEPTION; PRIORITY JOURNAL; REPORTER GENE; WILD TYPE;

ALKALINE PHOSPHATASE; BENZAMIDES; CELL LINE; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, LEUCINE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; MUTATION; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERAZINES; RECEPTORS, OPIOID, DELTA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 15744390094     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.077321     Document Type: Article

References (39)

1. Balboni G, Guerrini R, Salvadori S, Tomatis R, Bryant SD, Bianchi C, Attila M, and Lazarus LH (1997) Opioid diketopiperazines: synthesis and activity of a prototypic class of opioid antagonists. Biol Chem 378:19-29.
2. Befort K, Filliol D, Décaillot FM, Gavériaux-Ruff C, Hoehe MR, and Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:3130-3137.
3. Befort K, Tabbara L, Kling D, Maigret B, and Kieffer BL (1996) Role of transmembrane residues of the δ-opioid receptor in ligand recognition. J Biol Chem 271: 10161-10168.
4. Befort K, Zilliox C, Filliol D, S Y and Kieffer BL (1999) Constitutive activation of delta opioid receptor by mutations in transmembrane domain III and VII. J Biol Chem 274:18574-18581.
5. Behan DP and Chalmers DT (2001) The use of constitutively active receptors for drug discovery at the G protein-coupled receptor gene pool. Curr Opin Drug Discov Dev 4:548-560.
6. Bryant SD, Jinsmaa Y, Salvadori S, Okada Y, and Lazarus LH (2003) Dmt and opioid peptides: a potent alliance. Biopolymers 71:86-102.
7. Bryant SD, Salvadori S, Cooper PS, and Lazarus LH (1998) New D-opioid antagonists as pharmacological probes. Trends Pharmacol Sci 19:42-46.
8. Capasso S, Sica F, Mazzarella L, Balboni G, Guerrini R, and Salvadori S (1995) Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline-3-carboxylic acid at position 2. Int J Pept Protein Res 45:567-573.
9. Chiu TT, Yung LY, and Wong YH (1996) Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation. Mol Pharmacol 50:1651-1657.
10. Corbett AD, Paterson SJ, and Kosterlitz HW (1993) Selectivity of ligands for opioid receptors, in Handbook of Experimental Pharmacology, Opioids I (Herz A ed) pp 645-679, Springer-Verlag, Berlin, Germany.
11. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci 86:7321-7325.
12. Cotton R, Giles MG, Miller L, Shaw JS, and Timms D (1984) ICI 174864: a highly selective antagonist for the opioid δ-receptor. Eur J Pharmacol 97:331-332.
13. de Ligt RA, Kourounakis AP, and AP IJ (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12.
14. Decaillot FM, Befort K, Filliol D, Yue S, Walker P, and Kieffer BL (2003) Opioid receptor random mutagenesis reveals a mechanism for G protein-coupled receptor activation. Nat Struct Biol 10:629-636.
15. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, et al. (2000) Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195-200.
16. Hosohata K, Burkey TH, Alfaro-Lopez J, Hruby VJ, Roeske WR, and Yamamura HI (1999) (2S, 3R) TMT-L-Tic-OH is a potent inverse agonist at the human delta opioid receptor. Eur J Pharmacol 380:R9-R10.
17. Kieffer BL (1997) Molecular aspects of opioid receptors, in The Pharmacology of Pain (Dickenson A and Besson JM eds) pp 281-303, Springer-Verlag, Berlin, Germany.
18. Kieffer BL and Gavériaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285-306.
19. Labarre M, Butterworth J, St-Onge S, Payza K, Schmidhammer H, Salvadori S, Balboni G, Guerrini R, Bryant SD, and Lazarus LH (2000) Inverse agonism by dmt-Tic analogues and HS 378, a naltrindole analogue. Eur J Pharmacol 406:R1-R3.
20. Liu JG and Prather PL (2002) Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors. J Pharmacol Exp Ther 302:1070-1079.
21. Martin NA, Ruckle MB, VanHoof SL, and Prather PL (2002) Agonist, antagonist and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective delta-opioid receptor ligand. J Pharmacol Exp Ther 301:661-671.
22. Martin NA, Terruso MT, and Prather PL (2001) Agonist activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors. J Pharmacol Exp Ther 298:240-248.
23. Merkouris M, Mullaney I, Georgoussi Z, and Milligan G (1997) Regulation of spontaneous activity of the delta opioid receptor: studies of inverse agonism in intact cells. J Neurochem 69:2115-2122.
24. 35S]GTPγS binding assays. Trends Pharmacol Sci 24:87-90.
25. Mullaney I, Carr IC, and Milligan G (1996) Analysis of inverse agonism at the δ opioid receptor after expression in Rat-1 fibroblasts. Biochem J 315:227-234.
26. Neilan CL, Akil H, Woods JH, and Traynor JR (1999) Constitutive activity of the delta opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists. Br J Pharmacol 128:556-562.
27. Pineyro G, Azzi M, De Lean A, Schiller P, and Bouvier M (2001) Short-term inverse-agonist treatment induces reciprocal changes in delta-opioid agonist and inverse-agonist binding capacity. Mol Pharmacol 60:816-827.
28. Rossier O, Abuin L, Fanelli F, Leonardi A, and Cotecchia S (1999) Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)- adrenergic receptor subtypes. Mol Pharmacol 56:858-866.
29. Salvadori S, Attila M, Balboni G, Bianchi C, Bryant SD, Crescenzi O, Guerrini R, Picone D, Tancredi T, Temussi PA, et al. (1995) Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med 1:678-689.
30. Schiller PW, Nguyen TMD, Weltrowska G, Wilkes BC, Marsden BJ, Lemieux C, and Chung NN (1992) Differential stereochemical requirements of μ vs.∂ opioid receptors for ligand binding and signal transduction: development of a class of potent and highly ∂-selective peptide antagonists. Proc Natl Acad Sci USA 89:11871-11875.
31. Schiller PW, Weltrowska G, Berezowska I, Nguyen TM, Wilkes BC, Lemieux C, and Chung NN (1999) The TIPP opioid peptide family: development of delta antagonists, delta agonists and mixed mu agonist/delta antagonists. Biopolymers 51:411-425.
32. Schiller PW, Weltrowska G, Nguyen TM-D, Lemieux C, Chung NN, Zelent B, Wilkes BC, and Carpenter KA (1996) Peptides: chemistry, structure and biology, in Proceedings of the 14th American Peptide Symposium (Kaumaya TP, Hodges RS eds) 1995 June 18-23; Columbus, OH. pp 609-611, Mayflower Scientific Ltd., Kingswinford, United Kingdom.
33. Schmidhammer H, Krassnig R, Greiner E, Schultz J, White A, and Berzetei-Gurske IP (1998) Synthesis and biological evaluation of 14-alkoxymorphinans: XV. Novel delta opioid receptor antagonists with high affinity and selectivity in the 14-alkoxy-substituted indolomorphinan series. Helv Chim Acta 81:1064-1069.
34. Schutz J, Dersch CM, Horel R, Spetea M, Koch M, Meditz R, Greiner E, Rothman RB, and Schmidhammer H (2002) Synthesis and biological evaluation of 14-alkoxymorphinans: XVII. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans. J Med Chem 45:5378-5383.
35. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
36. Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
37. Szekeres PG and Traynor JR (1997) Delta opioid modulation of the binding of guanosine-5′-O-(3-[35S] thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther 283:1276-1284.
38. Whistler JL, Gerber BO, Meng EC, Baranski TJ, von Zastrow M, and Bourne HR (2002) Constitutive activation and endocytosis of the complement factor 5a receptor: evidence for multiple activated conformations of a G protein coupled receptor. Traffic 3:866-877.
39. Zaki PA, Keith DE Jr, Thomas JB, Carroll FI, and Evans CJ (2001) Agonist-, antagonist- and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation. J Pharmacol Exp Ther 298:1015-1020.